Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline J Stone

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of the American Academy of Dermatology|December 8, 2024
Smoking status is a negative predictor of six-month cutaneous lupus activity trends: A prospective cohort studyTyler B Cepica, Lillian Xie, Daniella F Faden, et al.
Journal of the American Academy of Dermatology|April 26, 2025
Regarding Wu et al's "response to Cepica et al's 'smoking status is a negative predictor of 6-month cutaneous lupus activity trends: A prospective cohort study'"Tyler B Cepica, Lillian Xie, Daniella F Faden, et al.
Journal of the American Academy of Dermatology|August 2, 2024
Cutaneous lupus erythematosus: Expanding clinical trial eligibility criteria based on quality of life dataDaniella F Faden, Lillian Xie, Caroline J Stone, et al.
JAMA Dermatology|September 25, 2024
Application of Risk-Based Cancer Screening in Patients With DermatomyositisCaroline J Stone, Daniella Forman Faden, Lillian Xie, et al.
JEADV Clinical Practice|January 12, 2026
Lifestyle, medication use, and age considerations with acne vulgaris: A prospective studyAshley M Snyder, Caroline J Stone, Nicole Ufkes, et al.
Journal of the American Academy of Dermatology|January 21, 2026
Cutaneous lupus damage is negatively predicted by disease subtype and systemic involvement and is associated with worse outcomes in body image - A prospective cohort studyTyler B Cepica, Grace Lu, Lillian Xie, et al.
The Journal of Investigative Dermatology|August 25, 2024
Classification of Cutaneous Melanoma and Melanocytic Nevi with MicroRNA Ratios Is Preserved in the Acral Melanoma SubtypeDekker C Deacon, Chris Stubben, Eleonora Marcacci, et al.
JID Innovations : Skin Science From Molecules to Population Health|October 15, 2024
Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension StudyCaroline J Stone, Geeta Ahuja, Lais Lopes Almeida Gomes, et al.
The Journal of Investigative Dermatology|January 16, 2026
Lenabasum, a cannabinoid type 2 receptor agonist, exerts anti-inflammatory effects in DermatomyositisDeAnna Diaz, Thomas Vazquez, Nilesh Kodali, et al.
Journal of the American Academy of Dermatology|March 6, 2025
Use of the Connor-Davidson Resilience Scale in a complex medical dermatology clinic: Cross-sectional study evaluating associations between resilience, health-related quality of life, and mental healthCaroline J Stone, Eliza Broadbent, Vikram N Sahni, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of the American Academy of Dermatology|December 8, 2024
Smoking status is a negative predictor of six-month cutaneous lupus activity trends: A prospective cohort studyTyler B Cepica, Lillian Xie, Daniella F Faden, et al.
Journal of the American Academy of Dermatology|April 26, 2025
Regarding Wu et al's "response to Cepica et al's 'smoking status is a negative predictor of 6-month cutaneous lupus activity trends: A prospective cohort study'"Tyler B Cepica, Lillian Xie, Daniella F Faden, et al.
Journal of the American Academy of Dermatology|August 2, 2024
Cutaneous lupus erythematosus: Expanding clinical trial eligibility criteria based on quality of life dataDaniella F Faden, Lillian Xie, Caroline J Stone, et al.
JAMA Dermatology|September 25, 2024
Application of Risk-Based Cancer Screening in Patients With DermatomyositisCaroline J Stone, Daniella Forman Faden, Lillian Xie, et al.
JEADV Clinical Practice|January 12, 2026
Lifestyle, medication use, and age considerations with acne vulgaris: A prospective studyAshley M Snyder, Caroline J Stone, Nicole Ufkes, et al.
Journal of the American Academy of Dermatology|January 21, 2026
Cutaneous lupus damage is negatively predicted by disease subtype and systemic involvement and is associated with worse outcomes in body image - A prospective cohort studyTyler B Cepica, Grace Lu, Lillian Xie, et al.
The Journal of Investigative Dermatology|August 25, 2024
Classification of Cutaneous Melanoma and Melanocytic Nevi with MicroRNA Ratios Is Preserved in the Acral Melanoma SubtypeDekker C Deacon, Chris Stubben, Eleonora Marcacci, et al.
JID Innovations : Skin Science From Molecules to Population Health|October 15, 2024
Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension StudyCaroline J Stone, Geeta Ahuja, Lais Lopes Almeida Gomes, et al.
The Journal of Investigative Dermatology|January 16, 2026
Lenabasum, a cannabinoid type 2 receptor agonist, exerts anti-inflammatory effects in DermatomyositisDeAnna Diaz, Thomas Vazquez, Nilesh Kodali, et al.
Journal of the American Academy of Dermatology|March 6, 2025
Use of the Connor-Davidson Resilience Scale in a complex medical dermatology clinic: Cross-sectional study evaluating associations between resilience, health-related quality of life, and mental healthCaroline J Stone, Eliza Broadbent, Vikram N Sahni, et al.
Pageof 2